Stay updated on Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page.

Latest updates to the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoChange DetectedThe webpage has added a section with helpful links provided by Pfizer, which includes information on how to obtain contact details for a study center nearby.SummaryDifference0.4%
- Check22 days agoChange DetectedThe page has been updated to reflect the discontinuation of the JAVELIN Ovarian PARP 100 study, with significant details about the study's design and previous results removed. Additionally, new identifiers and a revision number have been added.SummaryDifference23%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe webpage has removed a notice regarding heavy traffic affecting NLM-NCBI services and a link to obtain contact information for a study center provided by Pfizer.SummaryDifference1%
Stay in the know with updates to Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab+Talazoparib in Untreated Advanced Ovarian Cancer Clinical Trial page.